Tetra Bio-Pharma gets 5th orphan drug status for CBD topical

Mugglehead
By Jared GnamApr 23, 2020, 8:39 pm245 pts
Tetra Bio-Pharma Inc.‘s (TSX-V: TBP) strategy of developing a pipeline of cannabis-based drugs for rare diseases continues to gain U.S. FDA support. On Wednesday, the Ontario-based company shared details about its expanding orphan drug strategy inside the U.S. market. Tetra said it received a fifth orphan…

Read Article Share
Share Article
- email
- twitter
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

US House Committee Approves Bill to Close THCA ‘Loophole,’ Ban Intoxicating Hemp Products 57

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.